Skip to content

AXIM BIOTECHNOLOGIES, INC.: 10-Q filed 2016-11-30

What AXIM BIOTECHNOLOGIES, INC. reported in its quarterly report filed 2016-11-30 (fiscal Q3 2016): 33 published measures, 92 facts as tagged in accession 0001078782-16-003875.

This filing

Form
10-Q (quarterly report)
Filed
2016-11-30
Fiscal period
fiscal Q3 2016
Accession
0001078782-16-003875 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All AXIM BIOTECHNOLOGIES, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2016-09-301,230,350USD
At 2015-12-311,261,609USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2016-09-304,467,921USD
At 2015-12-312,956,811USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2016-09-30-3,237,571USD
At 2015-12-31-1,695,202USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2016-09-30870,633USD
At 2015-12-31134,170USD
At 2015-09-3043,260USD
At 2014-12-31661,128USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2016-07-01 to 2016-09-30-1,783,641USD92
2016-01-01 to 2016-09-30-4,626,317USD274
2015-07-01 to 2015-09-30-1,703,684USD92
2015-01-01 to 2015-09-30-3,771,318USD273

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2016-01-01 to 2016-09-30-761,694USD274
2015-01-01 to 2015-09-30-1,120,375USD273

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2016-01-01 to 2016-09-300USD274
2015-01-01 to 2015-09-3016,801USD273

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2016-07-01 to 2016-09-309,600USD92
2016-01-01 to 2016-09-3034,846USD274
2015-07-01 to 2015-09-3021,610USD92
2015-01-01 to 2015-09-3033,722USD273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2016-01-01 to 2016-09-301,498,157USD274
2015-01-01 to 2015-09-30519,308USD273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2016-01-01 to 2016-09-300USD274
2015-01-01 to 2015-09-30-16,801USD273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2016-09-30-16,886,047USD
At 2015-12-31-10,784,730USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2016-07-01 to 2016-09-300USD92
2016-01-01 to 2016-09-300USD274
2015-07-01 to 2015-09-300USD92
2015-01-01 to 2015-09-300USD273

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2016-09-3013,144USD
At 2015-12-3115,661USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2016-01-01 to 2016-09-301,424,935USD274
2015-01-01 to 2015-09-30586,125USD273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2016-07-01 to 2016-09-30-1,555,572USD92
2016-01-01 to 2016-09-30-2,989,239USD274
2015-07-01 to 2015-09-30-1,691,283USD92
2015-01-01 to 2015-09-30-3,740,601USD273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2016-09-301,154,039USD
At 2015-12-311,182,781USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2016-07-01 to 2016-09-30225,382USD92
2016-01-01 to 2016-09-30249,391USD274
2015-07-01 to 2015-09-3012,401USD92
2015-01-01 to 2015-09-3030,717USD273

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2016-09-304,150,653USD
At 2015-12-312,545,614USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2016-07-01 to 2016-09-301,551,511USD92
2016-01-01 to 2016-09-302,983,128USD274
2015-07-01 to 2015-09-301,680,063USD92
2015-01-01 to 2015-09-303,741,493USD273

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2016-09-30151,058USD
At 2015-12-31200,784USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2016-07-01 to 2016-09-30-4,061USD92
2016-01-01 to 2016-09-30-6,111USD274
2015-07-01 to 2015-09-30-11,220USD92
2015-01-01 to 2015-09-30892USD273

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2016-07-01 to 2016-09-301,462,954USD92
2016-01-01 to 2016-09-302,816,666USD274
2015-07-01 to 2015-09-301,546,136USD92
2015-01-01 to 2015-09-303,233,639USD273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2016-07-01 to 2016-09-3087,718USD92
2016-01-01 to 2016-09-30163,946USD274
2015-07-01 to 2015-09-30133,087USD92
2015-01-01 to 2015-09-30507,014USD273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2016-09-3051,492,659shares
At 2015-12-3139,633,706shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2016-09-3010,747,371USD
At 2015-12-319,032,865USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2016-09-303,636USD
At 2015-12-311,119USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2016-07-01 to 2016-09-30-1,783,641USD92
2016-01-01 to 2016-09-30-4,626,317USD274
2015-07-01 to 2015-09-30-1,703,684USD92
2015-01-01 to 2015-09-30-3,771,318USD273

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2016-01-01 to 2016-09-30-4,626,317USD274
2015-01-01 to 2015-09-30-3,771,318USD273

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2016-07-01 to 2016-09-30839USD92
2016-01-01 to 2016-09-302,516USD274
2015-07-01 to 2015-09-30840USD92
2015-01-01 to 2015-09-30840USD273

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2016-07-01 to 2016-09-30228,069USD92
2016-01-01 to 2016-09-301,637,078USD274
2015-07-01 to 2015-09-3012,401USD92
2015-01-01 to 2015-09-3030,717USD273

Income taxes paid, net

Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.

PeriodValueUnitDays
2016-01-01 to 2016-09-300USD274
2015-01-01 to 2015-09-30651USD273

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2016-01-01 to 2016-09-300USD274
2015-01-01 to 2015-09-3020,000USD273

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2016-01-01 to 2016-09-3039,973USD274
2015-01-01 to 2015-09-3032,830USD273

Inspect the source

Entity
AXIM BIOTECHNOLOGIES, INC. / CIK 0001514946
Captured
2026-09-20T09:13:30.666Z
SEC response SHA-256
5755093e2dfb1c20119737eacb251a5ef040e09cdc537c89d6edf9272249749e

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001514946.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))